Hepatitis C virus reactivation in cancer patients in the era of targeted therapies

World Journal of Gastroenterology

Volumn 20, Issue 22, 2014, Pages 6716-6724

  Yazici, Ozan ^a   Şendur, Mehmet Ali Nahit ^a   Aksoy, Sercan ^b  

^a ANKARA TRAINING AND RESEARCH HOSPITAL   (Turkey)

^b HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Cancer; Hepatitis C; Hepatitis C reactivation; Monoclonal antibodies; Rituximab

Indexed keywords

ALANINE AMINOTRANSFERASE; ALEMTUZUMAB; BRENTUXIMAB VEDOTIN; CETUXIMAB; EVEROLIMUS; IMATINIB; IPILIMUMAB; LAPATINIB; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PANITUMUMAB; PERTUZUMAB; RITUXIMAB; RNA; TRASTUZUMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; PROTEIN KINASE INHIBITOR;

ARTICLE; BIBLIOGRAPHIC DATABASE; CANCER GROWTH; CELL DIFFERENTIATION; DISEASE ASSOCIATION; DISEASE SEVERITY; HEPATITIS C; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOMODULATION; INFORMATION PROCESSING; MOLECULARLY TARGETED THERAPY; NEOPLASM; NONHODGKIN LYMPHOMA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; TREATMENT OUTCOME; VIRUS REACTIVATION; ADVERSE EFFECTS; DRUG EFFECTS; ENZYMOLOGY; GENETICS; HEPACIVIRUS; NEOPLASMS; PATHOGENICITY; SIGNAL TRANSDUCTION; VIROLOGY; VIRUS ACTIVATION;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; HEPACIVIRUS; HEPATITIS C; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; PROTEIN KINASE INHIBITORS; RISK FACTORS; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; VIRUS ACTIVATION;

EID: 84902138633     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i22.6716     Document Type: Article

References (67)

1. Wang F, Xu RH, Luo HY, Zhang DS, Jiang WQ, Huang HQ, Sun XF, Xia ZJ, Guan ZZ. Clinical and prognostic analysis of hepatitis B virus infection in diffuse large B-cell lymphoma. BMC Cancer 2008; 8: 115 [PMID: 18433487 DOI: 10.1186/1471-2407-8-115]
2. Dervite I, Hober D, Morel P. Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab. N Engl J Med 2001; 344: 68-69 [PMID: 11187122 DOI: 10.1056/NEJM200101043440120]
3. Yeo W, Chan TC, Leung NW, Lam WY, Mo FK, Chu MT, Chan HL, Hui EP, Lei KI, Mok TS, Chan PK. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol 2009; 27: 605-611 [PMID: 19075267 DOI: 10.1200/JCO.2008.18.0182]
4. Manzano-Alonso ML, Castellano-Tortajada G. Reactivation of hepatitis B virus infection after cytotoxic chemotherapy or immunosuppressive therapy. World J Gastroenterol 2011; 17: 1531-1537 [PMID: 21472116 DOI: 10.3748/wjg.v17.i12.1531]
5. Wang Y, Luo XM, Yang D, Zhang J, Zhuo HY, Zhang J, Jiang Y. Testing for hepatitis B infection in prospective chemotherapy patients: a retrospective study. World J Gastroenterol 2013; 19: 923-930 [PMID: 23429298 DOI: 10.3748/wjg. v19.i6.923]
6. Nicot F, Kamar N, Mariamé B, Rostaing L, Pasquier C, Izopet J. No evidence of occult hepatitis C virus (HCV) infection in serum of HCV antibody-positive HCV RNA-negative kidney-transplant patients. Transpl Int 2010; 23: 594-601 [PMID: 20002658 DOI: 10.1111/j.1432-2277.2009.01025.x]
7. Nguyen TT, Sedghi-Vaziri A, Wilkes LB, Mondala T, Pockros PJ, Lindsay KL, McHutchison JG. Fluctuations in viral load (HCV RNA) are relatively insignificant in untreated patients with chronic HCV infection. J Viral Hepat 1996; 3: 75-78 [PMID: 8811641 DOI: 10.1111/j.1365-2893.1996. tb00084.x]
8. Fanning L, Kenny-Walsh E, Levis J, Choudhury KR, Cannon B, Sheehan M, Whelton M, Shanahan F. Natural fluctuations of hepatitis C viral load in a homogeneous patient population: a prospective study. Hepatology 2000; 31: 225-229 [PMID: 10613750]
9. National Institutes of Health Consensus Development Conference Panel statement: management of hepatitis C. Hepatology 1997; 26: 2S-10S [PMID: 9305656 DOI: 10.1002/hep.510260701]
10. Vento S, Cainelli F, Mirandola F, Cosco L, Di Perri G, Solbiati M, Ferraro T, Concia E. Fulminant hepatitis on withdrawal of chemotherapy in carriers of hepatitis C virus. Lancet 1996; 347: 92-93 [PMID: 8538348 DOI: 10.1016/S0140-6736(96)90212-3]
11. Takai S, Tsurumi H, Ando K, Kasahara S, Sawada M, Yamada T, Hara T, Fukuno K, Takahashi T, Oyama M, Onishi H, Tomita E, Takami T, Imawari M, Moriwaki H. Prevalence of hepatitis B and C virus infection in haematological malignancies and liver injury following chemotherapy. Eur J Haematol 2005; 74: 158-165 [PMID: 15654908 DOI: 10.1111/ j.1600-0609.2004.00376.x]
12. Watanabe T, Tanaka Y. Reactivation of hepatitis viruses following immunomodulating systemic chemotherapy. Hepatol Res 2013; 43: 113-121 [PMID: 23186317 DOI: 10.1111/ hepr.12014]
13. Eisenberg R, Looney RJ. The therapeutic potential of anti-CD20 "what do B-cells do?". Clin Immunol 2005; 117: 207-213 [PMID: 16169773 DOI: 10.1016/j.clim.2005.08.006]
14. Leget GA, Czuczman MS. Use of rituximab, the new FDAapproved antibody. Curr Opin Oncol 1998; 10: 548-551 [PMID: 9818234 DOI: 10.1097/00001622-199811000-00012]
15. Ennishi D, Maeda Y, Niitsu N, Kojima M, Izutsu K, Takizawa J, Kusumoto S, Okamoto M, Yokoyama M, Takamatsu Y, Sunami K, Miyata A, Murayama K, Sakai A, Matsumoto M, Shinagawa K, Takaki A, Matsuo K, Kinoshita T, Tanimoto M. Hepatic toxicity and prognosis in hepatitis C virus-infected patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy regimens: a Japanese multicenter analysis. Blood 2010; 116: 5119-5125 [PMID: 20823454 DOI: 10.1182/blood-2010-06-289231]
16. Aksoy S, Abali H, Kilickap S, Erman M, Kars A. Accelerated hepatitis C virus replication with rituximab treatment in a non-Hodgkin's lymphoma patient. Clin Lab Haematol 2006; 28: 211-214 [PMID: 16706940 DOI: 10.1111/j.1365-2257.2006.00779. x]
17. Ennishi D, Terui Y, Yokoyama M, Mishima Y, Takahashi S, Takeuchi K, Okamoto H, Tanimoto M, Hatake K. Monitoring serum hepatitis C virus (HCV) RNA in patients with HCV-infected CD20-positive B-cell lymphoma undergoing rituximab combination chemotherapy. Am J Hematol 2008; 83: 59-62 [PMID: 17712791 DOI: 10.1002/ajh.21022]
18. Visco C, Arcaini L, Brusamolino E, Burcheri S, Ambrosetti A, Merli M, Bonoldi E, Chilosi M, Viglio A, Lazzarino M, Pizzolo G, Rodeghiero F. Distinctive natural history in hepatitis C virus positive diffuse large B-cell lymphoma: analysis of 156 patients from northern Italy. Ann Oncol 2006; 17: 1434-1440 [PMID: 16766591 DOI: 10.1093/annonc/mdl131]
19. Nosotti L, D'Andrea M, Pitidis A, Pimpinelli F, Dessanti ML, Pisani F, Vignally P, Petti MC. Hepatitis C virus infection prevalence and liver dysfunction in a cohort of B-cell non-Hodgkin's lymphoma patients treated with immunochemotherapy. Scand J Infect Dis 2012; 44: 70-73 [PMID: 21905952 DOI: 10.3109/00365548.2011.611819]
20. Aksoy S, Harputluoglu H, Kilickap S, Dede DS, Dizdar O, Altundag K, Barista I. Rituximab-related viral infections in lymphoma patients. Leuk Lymphoma 2007; 48: 1307-1312 [PMID: 17613758 DOI: 10.1080/10428190701411441]
21. Cerny A, Chisari FV. Pathogenesis of chronic hepatitis C: immunological features of hepatic injury and viral persistence. Hepatology 1999; 30: 595-601 [PMID: 10462362 DOI: 10.1002/hep.510300312]
22. Vigna-Perez M, Hernández-Castro B, Paredes-Saharopulos O, Portales-Pérez D, Baranda L, Abud-Mendoza C, González-Amaro R. Clinical and immunological effects of Rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study. Arthritis Res Ther 2006; 8: R83 [PMID: 16677395 DOI: 10.1186/ar1954]
23. Dammacco F, Sansonno D, Piccoli C, Racanelli V, D'Amore FP, Lauletta G. The lymphoid system in hepatitis C virus infection: autoimmunity, mixed cryoglobulinemia, and Overt B-cell malignancy. Semin Liver Dis 2000; 20: 143-157 [PMID: 10946420 DOI: 10.1055/s-2000-9613]
24. Dizdar O, Tapan U, Aksoy S, Harputluoglu H, Kilickap S, Barista I. Liver dysfunction after chemotherapy in lymphoma patients infected with hepatitis C. Eur J Haematol 2008; 80: 381-385 [PMID: 18221389 DOI: 10.1111/j.1600-0609.2008.01039. x]
25. Coppola N, Pisaturo M, Guastafierro S, Tonziello G, Sica A, Iodice V, Sagnelli C, Ferrara MG, Sagnelli E. Increased hepatitis C viral load and reactivation of liver disease in HCV RNA-positive patients with onco-haematological disease undergoing chemotherapy. Dig Liver Dis 2012; 44: 49-54 [PMID: 21885355 DOI: 10.1016/j.dld.2011.07.016]
26. Lake-Bakaar G, Dustin L, McKeating J, Newton K, Freeman V, Frost SD. Hepatitis C virus and alanine aminotransferase kinetics following B-lymphocyte depletion with rituximab: evidence for a significant role of humoral immunity in the control of viremia in chronic HCV liver disease. Blood 2007; 109: 845-846 [PMID: 17210867 DOI: 10.1182/ blood-2006-08-041525]
27. Vallisa D, Bernuzzi P, Arcaini L, Sacchi S, Callea V, Marasca R, Lazzaro A, Trabacchi E, Anselmi E, Arcari AL, Moroni C, Bertè R, Lazzarino M, Cavanna L. Role of anti-hepatitis C virus (HCV) treatment in HCV-related, low-grade, B-cell, non-Hodgkin's lymphoma: a multicenter Italian experience. J Clin Oncol 2005; 23: 468-473 [PMID: 15659492 DOI: 10.1200/JCO.2005.06.008]
28. Mazzaro C, De Re V, Spina M, Dal Maso L, Festini G, Comar C, Tirelli U, Pozzato G. Pegylated-interferon plus ribavirin for HCV-positive indolent non-Hodgkin lymphomas. Br J Haematol 2009; 145: 255-257 [PMID: 19239472 DOI: 10.1111/j.1365-2141.2008.07565.x]
29. Yeo W, Johnson PJ. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology 2006; 43: 209-220 [PMID: 16440366 DOI: 10.1002/ hep.21051]
30. Osterborg A, Dyer MJ, Bunjes D, Pangalis GA, Bastion Y, Catovsky D, Mellstedt H. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia. J Clin Oncol 1997; 15: 1567-1574 [PMID: 9193354]
31. Iannitto E, Minardi V, Calvaruso G, Mulè A, Ammatuna E, Di Trapani R, Ferraro D, Abbadessa V, Craxí A, Di Stefano R. Hepatitis B virus reactivation and alemtuzumab therapy. Eur J Haematol 2005; 74: 254-258 [PMID: 15693796 DOI: 10.1111/j.1600-0609.2004.00375.x]
32. Anoop P, Wotherspoon A, Matutes E. Severe liver dysfunction from hepatitis C virus reactivation following alemtuzumab treatment for chronic lymphocytic leukaemia. Br J Haematol 2010; 148: 484-486 [PMID: 19874308 DOI: 10.1111/ j.1365-2141.2009.07972.x]
33. Kennedy MK, Willis CR, Armitage RJ. Deciphering CD30 ligand biology and its role in humoral immunity. Immunology 2006; 118: 143-152 [PMID: 16771849 DOI: 10.1111/ j.1365-2567.2006.02354.x]
34. van de Donk NW, Dhimolea E. Brentuximab vedotin. MAbs 2012; 4: 458-465 [PMID: 22684302 DOI: 10.4161/mabs.20230]
35. Cheng AL, Kang YK, Lin DY, Park JW, Kudo M, Qin S, Chung HC, Song X, Xu J, Poggi G, Omata M, Pitman Lowenthal S, Lanzalone S, Yang L, Lechuga MJ, Raymond E. Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial. J Clin Oncol 2013; 31: 4067-4075 [PMID: 24081937 DOI: 10.1200/ JCO.2012.45.8372]
36. Rao J, Feng M, Qian X, Li G, Wang X, Zhang F, Lu L. Liver transplantation treating the patient with hepatic failure associated with sorafenib treatment: report of a case. Hepatogastroenterology 2013; 60: 1317-1319 [PMID: 23933924 DOI: 10.5754/hge13185]
37. Schramm C, Schuch G, Lohse AW. Sorafenib-induced liver failure. Am J Gastroenterol 2008; 103: 2162-2163 [PMID: 18796127 DOI: 10.1111/j.1572-0241.2008.01982_19.x]
38. Supekova L, Supek F, Lee J, Chen S, Gray N, Pezacki JP, Schlapbach A, Schultz PG. Identification of human kinases involved in hepatitis C virus replication by small interference RNA library screening. J Biol Chem 2008; 283: 29-36 [PMID: 17951261 DOI: 10.1074/jbc.M703988200]
39. Himmelsbach K, Sauter D, Baumert TF, Ludwig L, Blum HE, Hildt E. New aspects of an anti-tumour drug: sorafenib efficiently inhibits HCV replication. Gut 2009; 58: 1644-1653 [PMID: 19710032 DOI: 10.1136/gut.2009.182212]
40. Hutson TE, Davis ID, Machiels JP, De Souza PL, Rottey S, Hong BF, Epstein RJ, Baker KL, McCann L, Crofts T, Pandite L, Figlin RA. Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma. J Clin Oncol 2010; 28: 475-480 [PMID: 20008644 DOI: 10.1200/JCO.2008.21.6994]
41. Escudier B, Gore M. Axitinib for the management of metastatic renal cell carcinoma. Drugs R D 2011; 11: 113-126 [PMID: 21679004 DOI: 10.2165/11591240-000000000-00000]
42. Ripault MP, Pinzani V, Fayolle V, Pageaux GP, Larrey D. Crizotinib-induced acute hepatitis: first case with relapse after reintroduction with reduced dose. Clin Res Hepatol Gastroenterol 2013; 37: e21-e23 [PMID: 23182672 DOI: 10.1016/ j.clinre.2012.10.003]
43. Ikeda K, Shiga Y, Takahashi A, Kai T, Kimura H, Takeyama K, Noji H, Ogawa K, Nakamura A, Ohira H, Sato Y, Maruyama Y. Fatal hepatitis B virus reactivation in a chronic myeloid leukemia patient during imatinib mesylate treatment. Leuk Lymphoma 2006; 47: 155-157 [PMID: 16321842 DOI: 10.1080/14639230500236818]
44. Kang BW, Lee SJ, Moon JH, Kim SN, Chae YS, Kim JG, Hwang YJ, Sohn SK. Chronic myeloid leukemia patient manifesting fatal hepatitis B virus reactivation during treatment with imatinib rescued by liver transplantation: case report and literature review. Int J Hematol 2009; 90: 383-387 [PMID: 19641858 DOI: 10.1007/s12185-009-0386-2]
45. Wang YD, Cui GH, You Y, Li M, Xia J, Hu Y. [Reactivation of chronic hepatitis B infection related to imatinib mesylate therapy in patients with chronic myeloid leukemia: two cases report and literatures review]. Zhonghua Xue Ye Xue Za Zhi 2012; 33: 743-746 [PMID: 23336229 DOI: 10.3760/cma. j.issn.0253-2727.2012.09.012]
46. Lai GM, Yan SL, Chang CS, Tsai CY. Hepatitis B reactivation in chronic myeloid leukemia patients receiving tyrosine kinase inhibitor. World J Gastroenterol 2013; 19: 1318-1321 [PMID: 23483799 DOI: 10.3748/wjg.v19.i8.1318]
47. Seggewiss R, Loré K, Greiner E, Magnusson MK, Price DA, Douek DC, Dunbar CE, Wiestner A. Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner. Blood 2005; 105: 2473-2479 [PMID: 15572591 DOI: 10.1182/blood-2004-07-2527]
48. Appel S, Boehmler AM, Grünebach F, Müller MR, Rupf A, Weck MM, Hartmann U, Reichardt VL, Kanz L, Brümmendorf TH, Brossart P. Imatinib mesylate affects the development and function of dendritic cells generated from CD34+ peripheral blood progenitor cells. Blood 2004; 103: 538-544 [PMID: 14504105 DOI: 10.1182/blood-2003-03-0975]
49. Castillo-Rama M, Grande C, Martínez-Sanchez P, Olavarria E, Marín D, Paz-Artal E, Andrés A, Morales JM. [Molecular remission of chronic myeloid leukaemia in a patient with hepatitis and a second kidney transplant]. Nefrologia 2009; 29: 604-607 [PMID: 19936007 DOI: 10.3265/Nefrologia. 2009.29.6.5346.en.full]
50. Lin AY, Fisher GA, So S, Tang C, Levitt L. Phase II study of imatinib in unresectable hepatocellular carcinoma. Am J Clin Oncol 2008; 31: 84-88 [PMID: 18376233 DOI: 10.1097/ COC.0b013e3181131db9]
51. Grünwald V, Weikert S, Pavel ME, Hörsch D, Lüftner D, Janni W, Geberth M, Weber MM. Practical management of everolimus-related toxicities in patients with advanced solid tumors. Onkologie 2013; 36: 295-302 [PMID: 23689226 DOI: 10.1159/000350625]
52. Teng CF, Wu HC, Tsai HW, Shiah HS, Huang W, Su IJ. Novel feedback inhibition of surface antigen synthesis by mammalian target of rapamycin (mTOR) signal and its implication for hepatitis B virus tumorigenesis and therapy. Hepatology 2011; 54: 1199-1207 [PMID: 21735472 DOI: 10.1002/hep.24529]
53. Mizuno S, Yamagishi Y, Ebinuma H, Nakamoto N, Katahira M, Sasaki A, Sakamoto M, Suzuki H, Kanai T, Hibi T. Progressive liver failure induced by everolimus for renal cell carcinoma in a 58-year-old male hepatitis B virus carrier. Clin J Gastroenterol 2013; 6: 188-192 [PMID: 23606919 DOI: 10.1007/s12328-013-0371-4]
54. Sezgin Göksu S, Bilal S, Coşkun HŞ. Hepatitis B reactivation related to everolimus. World J Hepatol 2013; 5: 43-45 [PMID: 23383366 DOI: 10.4254/wjh.v5.i1.43]
55. Baselga J, Campone M, Piccart M, Burris HA, Rugo HS, Sahmoud T, Noguchi S, Gnant M, Pritchard KI, Lebrun F, Beck JT, Ito Y, Yardley D, Deleu I, Perez A, Bachelot T, Vittori L, Xu Z, Mukhopadhyay P, Lebwohl D, Hortobagyi GN. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 2012; 366: 520-529 [PMID: 22149876 DOI: 10.1056/NEJMoa1109653]
56. Casanovas T, Argudo A, Peña-Cala MC. Effectiveness and safety of everolimus in the treatment of autoimmune hepatitis related to anti-hepatitis C virus therapy after liver transplant: three case reports. Transplant Proc 2011; 43: 2233-2236 [PMID: 21839242 DOI: 10.1016/j.transproceed.2011.05.028]
57. Casanovas T, Argudo A, Peña-Cala MC. Everolimus in clinical practice in long-term liver transplantation: an observational study. Transplant Proc 2011; 43: 2216-2219 [PMID: 21839237 DOI: 10.1016/j.transproceed.2011.06.015]
58. Choueiri TK, Je Y, Sonpavde G, Richards CJ, Galsky MD, Nguyen PL, Schutz F, Heng DY, Kaymakcalan MD. Incidence and risk of treatment-related mortality in cancer patients treated with the mammalian target of rapamycin inhibitors. Ann Oncol 2013; 24: 2092-2097 [PMID: 23658373 DOI: 10.1093/annonc/mdt155]
59. Matsumoto A, Ichikawa T, Nakao K, Miyaaki H, Hirano K, Fujimito M, Akiyama M, Miuma S, Ozawa E, Shibata H, Takeshita S, Yamasaki H, Ikeda M, Kato N, Eguchi K. Interferon-alpha-induced mTOR activation is an anti-hepatitis C virus signal via the phosphatidylinositol 3-kinase-Akt-independent pathway. J Gastroenterol 2009; 44: 856-863 [PMID: 19436942 DOI: 10.1007/s00535-009-0075-1]
60. Miura Y, Theriault RL, Naito Y, Suyama K, Shimomura A, Iwatani T, Miura D, Kawabata H, Kumada H, Takano T. The safety of chemotherapy for breast cancer patients with hepatitis C virus infection. J Cancer 2013; 4: 519-523 [PMID: 23901352 DOI: 10.7150/jca.6231]
61. Tamori A, Kawajiri H, Takashima T, Motoyama H, Morikawa H, Enomoto M, Hirakawa K, Kawada N. Could trastuzumab suppress hepatitis C virus in a patient with chronic hepatitis and breast cancer? Am J Gastroenterol 2011; 106: 1865-1866 [PMID: 21979218 DOI: 10.1038/ajg.2011.258]
62. Lupberger J, Zeisel MB, Xiao F, Thumann C, Fofana I, Zona L, Davis C, Mee CJ, Turek M, Gorke S, Royer C, Fischer B, Zahid MN, Lavillette D, Fresquet J, Cosset FL, Rothenberg SM, Pietschmann T, Patel AH, Pessaux P, Doffoël M, Raffelsberger W, Poch O, McKeating JA, Brino L, Baumert TF. EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy. Nat Med 2011; 17: 589-595 [PMID: 21516087 DOI: 10.1038/nm.2341]
63. Diao J, Pantua H, Ngu H, Komuves L, Diehl L, Schaefer G, Kapadia SB. Hepatitis C virus induces epidermal growth factor receptor activation via CD81 binding for viral internalization and entry. J Virol 2012; 86: 10935-10949 [PMID: 22855500 DOI: 10.1128/JVI.00750-12]
64. Lupberger J, Duong FH, Fofana I, Zona L, Xiao F, Thumann C, Durand SC, Pessaux P, Zeisel MB, Heim MH, Baumert TF. Epidermal growth factor receptor signaling impairs the antiviral activity of interferon-alpha. Hepatology 2013; 58: 1225-1235 [PMID: 23519785 DOI: 10.1002/hep.26404]
65. Nakamoto N, Cho H, Shaked A, Olthoff K, Valiga ME, Kaminski M, Gostick E, Price DA, Freeman GJ, Wherry EJ, Chang KM. Synergistic reversal of intrahepatic HCVspecific CD8 T cell exhaustion by combined PD-1/CTLA-4 blockade. PLoS Pathog 2009; 5: e1000313 [PMID: 19247441 DOI: 10.1371/journal.ppat.1000313]
66. Minter S, Willner I, Shirai K. Ipilimumab-induced hepatitis C viral suppression. J Clin Oncol 2013; 31: e307-e308 [PMID: 23690418 DOI: 10.1200/JCO.2012.46.5831]
67. Sharma A, Thompson JA, Repaka A, Mehnert JM. Ipilimumab administration in patients with advanced melanoma and hepatitis B and C. J Clin Oncol 2013; 31: e370-e372 [PMID: 23775956 DOI: 10.1200/JCO.2012.47.1946]